SCHEMBL8557424

SCHEMBL8557424

CSc1nc(C)cc(OCc2ccccc2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.61
MEN1 O00255 2/20 0.61
HTT P42858 2/20 0.61
THRB P10828 1/20 0.57
ALDH1A1 P00352 3/20 0.56
GAA P10253 1/20 0.56
ADORA3 P0DMS8 1/20 0.47
ADORA1 P30542 1/20 0.47
PTGES O14684 1/20 0.46
ALOX5 P09917 1/20 0.46
TSHR P16473 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NUDT1 P36639 1/20 0.46
KDM4E B2RXH2 3/20 0.46
LMNA P02545 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
MAPK1 P28482 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
POLB P06746 1/20 0.44
TP53 P04637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8562004 0.85 ALOX5 (0.46) KMT2AMEN1HTTTHRBALDH1A1
SCHEMBL18689633 0.84 KMT2A (0.54) KMT2AMEN1HTTTHRBALDH1A1
SCHEMBL8558770 0.84 ALOX5 (0.48) KMT2AMEN1HTTTHRBGAA
SCHEMBL8561075 0.84 ALOX5 (0.48) KMT2AMEN1HTTTHRBALDH1A1
SCHEMBL8561459 0.80 PTGES (0.43) KMT2AMEN1HTTTHRBALDH1A1
SCHEMBL1564355 0.80 ALDH1A1 (0.64) KMT2AMEN1HTTALDH1A1GAA
SCHEMBL31493092 0.78 ALDH1A1 (0.52) KMT2AMEN1HTTALDH1A1GAA
SCHEMBL11464975 0.78 NUDT1 (0.67) KMT2AMEN1HTTALDH1A1GAA
SCHEMBL3545118 0.78 ALKBH1 (0.43) KMT2AMEN1HTTGAAADORA3
SCHEMBL12157689 0.78 ALDH1A1 (0.51) KMT2AMEN1HTTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250313554-A1 PTPN2 INHIBITORS MONDEGO BIO, LDA. (PT) 2025-10-09 US disclosed
EP-4522594-A1 PTPN2 INHIBITORS Ness Therapeutics, Inc. (US) 2025-03-19 EP disclosed
WO-2023220572-A1 PTPN2 INHIBITORS NESS THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
WO-2023220572-A1 PTPN2 INHIBITORS NESS THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
US-5726128-A Benzyloxypyrimidine derivative, processes for producing the same and herbicidal composition KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1998-03-10 US disclosed
EP-0707001-A1 Benzyloxypyrimidine derivative, processes for producing the same and herbicidal composition KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1996-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250313554-A1 PTPN2 INHIBITORS PTPN2, PTPN1, PTPRJ KMT2A 1912/4885MEN1 3303/4885HTT 1504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.